SCHEMBL13656185

SCHEMBL13656185

CC(=O)NC(C1=C(C)C(=O)c2ccccc2C1=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
APEX1 P27695 1/20 0.43
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CDC25B P30305 3/20 0.41
S100A4 P26447 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
HSP90AA1 P07900 2/20 0.40
HSP90AB1 P08238 2/20 0.40
MAPT P10636 2/20 0.40
APAF1 O14727 1/20 0.40
MITF O75030 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CDC25A P30304 2/20 0.39
MAP2K7 O14733 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13649338 0.80 HSP90AA1 (0.45) LMNAALDH1A1KDM4EAPEX1MEN1
SCHEMBL425361 0.78 ALDH1A1 (0.58) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL13649346 0.75 L3MBTL1 (0.48) LMNAAPEX1MEN1KMT2ACDC25B
SCHEMBL14409534 0.74 LMNA (0.72) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL7915423 0.73 CDC25B (0.48) LMNAALDH1A1KDM4EAPEX1MEN1
SCHEMBL26829307 0.70 LMNA (0.53) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL14409536 0.70 SLC6A9 (0.54) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL7832731 0.70 HDAC1 (0.47)
SCHEMBL12761943 0.69 AURKA (0.48) LMNAALDH1A1KDM4EAPEX1MEN1
SCHEMBL28137499 0.69 POLB (0.70) LMNAALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS FLUOFARMA (FR) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247472-A1 TYPE 1, 4-NAPHTOQUINONE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USE OF THESE COMPOUNDS AS ANTI-CANCER AGENTS CCNA1, MKI67, CCNT1 LMNA 173/4885ALDH1A1 709/4885KDM4E 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.